VC isn't VC anymore – understanding the rise of Cancer Capital
Recent analysis argues that traditional venture capital models are fading, replaced by what some call “cancer capital.” This new approach prioritizes rapid, high‑risk funding of startups with aggressive growth targets, often disregarding long‑term sustainability. The piece examines how this shift affects startup ecosystems, investor behavior, and the broader tech industry’s funding landscape, and raises concerns about ethical implications.